TriangleCARv3-TEAM-E T cells (NCT05660369)
CARv3-TEAM-E T cells trial for Glioblastoma (NCT05660369). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
Glioblastoma almost always returns. Part of the reason: the tumor is a patchwork. Kill the cells with one marker, and the rest grow on.
The idea: an immune cell that attacks two targets at once.
A patient's own T cells are fitted with a receptor for EGFRvIII, a mutant protein found only on tumor cells. The same cells also secrete a small antibody that grabs normal EGFR, common across glioblastoma, and pulls other T cells in to attack it. They go through a reservoir into the fluid around the brain.
In the first three patients, tumors shrank within days, though for two it did not last.
INCIPIENT, at Mass General with William Curry, now asks about dose and safety. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.